Max Horlbeck, MD, PhD
Attending Physician, Division of Genetics and Genomics
Assistant Professor of Genetics, Harvard Medical School
Image
Max Horlbeck, MD, PhD
Attending Physician, Division of Genetics and Genomics
Assistant Professor of Genetics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Columbia University
2011
New York
NY
Graduate School
University of California, San Francisco
2019
San Francisco
CA
Medical School
University of California, San Francisco
2019
San Francisco
CA
Residency
Pediatrics and Medical Genetics
Boston Combined Residency Program (BCRP)
2024
Boston
MA
Certifications
American Board of Medical Genetics and Genomics (Clinical Genetics)
American Board of Pediatrics (General)
Professional History
Dr. Horlbeck is a Clinical Geneticist and Researcher at Boston Children’s Hospital who specializes in genetic disorders of chromatin machinery in the clinic and his laboratory. This is a large group of genetic conditions that includes Kabuki, Kleefstra, Wiedemann-Steiner, Arboleda-Tham, and O'Donnell-Luria-Rodan syndromes.
He is originally from Westfield, New Jersey and obtained an MD and PhD from the University of California, San Francisco. During his PhD research, he developed tools based on CRISPR technology that enable researchers to systematically turn genes on and off in order to discover new gene functions. In postdoctoral work at Harvard and the Broad Institute, he developed a new method for understanding how genes are regulated in development. He now aims to bring these tools together with the goal of better understanding and treating disorders of chromatin biology.
Publications
Multiscale footprints reveal the organization of cis-regulatory elements. View Abstract
Novel Phenotypes and Genotype-Phenotype Correlations in a Large Clinical Cohort of Patients With Kleefstra Syndrome. View Abstract
FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer. View Abstract
CRISPRi screens identify the lncRNA, LOUP, as a multifunctional locus regulating macrophage differentiation and inflammatory signaling. View Abstract
FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer. View Abstract
Single-cell multi-scale footprinting reveals the modular organization of DNA regulatory elements. View Abstract
GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma. View Abstract
Dual genome-wide coding and lncRNA screens in neural induction of induced pluripotent stem cells. View Abstract
Genome-wide CRISPRi screening identifies OCIAD1 as a prohibitin client and regulatory determinant of mitochondrial Complex III assembly in human cells. View Abstract
High-content imaging-based pooled CRISPR screens in mammalian cells. View Abstract
Genome-Scale Perturbation of Long Noncoding RNA Expression Using CRISPR Interference. View Abstract
Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent. View Abstract
CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. View Abstract
Fitness effects of CRISPR/Cas9-targeting of long noncoding RNA genes. View Abstract
Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs. View Abstract
New factors for protein transport identified by a genome-wide CRISPRi screen in mammalian cells. View Abstract
Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. View Abstract
Cellular response to small molecules that selectively stall protein synthesis by the ribosome. View Abstract
A high-throughput screen of real-time ATP levels in individual cells reveals mechanisms of energy failure. View Abstract
Mapping the Genetic Landscape of Human Cells. View Abstract
Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. View Abstract
Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. View Abstract
Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element. View Abstract
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. View Abstract
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. View Abstract
A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response. View Abstract
CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. View Abstract
Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. View Abstract
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. View Abstract
Single-cell analysis of long non-coding RNAs in the developing human neocortex. View Abstract
Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. View Abstract
Nucleosomes impede Cas9 access to DNA in vivo and in vitro. View Abstract
CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. View Abstract
Next-generation libraries for robust RNA interference-based genome-wide screens. View Abstract
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. View Abstract
A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. View Abstract
ER cargo properties specify a requirement for COPII coat rigidity mediated by Sec13p. View Abstract
[Initial results following implantation of silastic wrist joint prostheses in patients with chronic polyarthritis with additional use of titanium grommets]. View Abstract
Locations